Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
Type:
Grant
Filed:
August 10, 2020
Date of Patent:
September 12, 2023
Assignee:
Anji Bruno, LLC
Inventors:
Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel